cGMP-Dependent Protein Kinase I Is Crucial for Angiogenesis and Postnatal Vasculogenesis

Alexandra Aicher 1,*a, Christopher Heeschen 1,*b, Susanne Feil 2, Franz Hofmann 3, Michael E. Mendelsohn 4, Robert Feil 2, Stefanie Dimmeler 1*

1 Department of Internal Medicine III, J. W. Goethe University, Frankfurt, Germany, 2 Interfakultäres Institut für Biochemie, Universität Tübingen, Tübingen, Germany, 3 Institut für Pharmakologie und Toxikologie, Technische Universität München, München, Germany, 4 Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States of America

Abstract

Background: Endothelium-derived nitric oxide plays an important role for the bone marrow microenvironment. Since several important effects of nitric oxide are mediated by cGMP-dependent pathways, we investigated the role of the cGMP downstream effector cGMP-dependent protein kinase I (cGKI) on postnatal neovascularization.

Methodology/Principal Findings: In a disc neovascularization model, cGKI−/− mice showed an impaired neovascularization as compared to their wild-type (WT) littermates. Infusion of WT, but not cGKI−/− bone marrow progenitors rescued the impaired ingrowth of new vessels in cGKI-deficient mice. Bone marrow progenitors from cGKI−/− mice showed reduced proliferation and survival rates. In addition, we used cGKI Δleucine zipper mutant (LZM) mice as model for cGKI deficiency. LZM mice harbor a mutation in the cGKI leucine zipper that prevents interaction with downstream signaling molecules. Consistently, LZM mice exhibited reduced numbers of vasculogenic progenitors and impaired neovascularization following hindlimb ischemia compared to WT mice.

Conclusions/Significance: Our findings demonstrate that the cGMP-cGKI pathway is critical for postnatal neovascularization and establish a new role for cGKI in vasculogenesis, which is mediated by bone marrow-derived progenitors.

Introduction

Mice deficient for endothelial nitric oxide synthase (eNOS) show a defective neovascularization [1], which is, at least in part, related to an impaired mobilization of vasculogenic progenitor cells [2]. In contrast to angiogenesis, which results from the migration and proliferation of pre-existing mature endothelial cells [3], vasculogenesis is based on the recruitment and incorporation of bone marrow-derived progenitors to sites of neovascularization [4–6]. Endothelium-derived nitric oxide (NO) plays an essential role in the bone marrow microenvironment and is essential for the mobilization of progenitor cells [2,7–10]. However, NO bioavailability is typically reduced in patients with diabetes, coronary artery disease, and ischemic cardiomyopathy (ICMP) [11–13]. Consequently, bone marrow progenitors from patients with diabetes or ICMP show a reduced neovascularization capacity, which is a drawback for their use in cell therapy [14]. The impaired functional activity of bone marrow cells from patients could be partially restored after pharmacological enhancement of eNOS expression or nitric oxide donors, which highlights the important role of endothelium-derived NO for neovascularization [15,16]. One important downstream signaling pathway of endothelium-derived NO is mediated by cyclic guanosine monophosphate (cGMP) as second messenger. Elevated levels of intracellular cGMP modulate phosphodiesterases, open cation channels, and activate cGMP-dependent protein kinases (cGK; also called protein kinase G; PKG) [17]. The cGKs belong to the family of serine/threonine kinases [18,19]. Mammals have two cGK genes, which encode cGKI and cGKII. The NH2-terminus of cGKI is encoded by two alternative exons producing the isoforms cGKIα and cGKIβ. The cGKI isoforms are soluble enzymes and interact with several proteins through their NH2-termini containing leucine/isoleucine zippers (LZ). Here, we investigated the role of the NO downstream signaling protein cGKI for postnatal neovascularization in two different models for cGKI deficiency, cGKI−/− mice and mice with a cGKI mutation that affects downstream signaling (LZM mice).
Results

To study the role of cGKI for neovascularization in vivo, we subcutaneously implanted discs into the flanks of cGKI−/− mice and their wild-type (WT) littermates. The implantation of discs stimulates neovascularization due to sterile inflammation. After two weeks, animals were sacrificed, and, prior to explantation of the disks, fluorescent microspheres were infused into the circulation to demonstrate the perfusion of the vessels growing from the rim to the center of the disc. Gross examination of the explanted disk already revealed a clear reduction in the vascularized area for cGKI−/− mice compared to WT (Fig. 1A). In addition, formation of neovessels was demonstrated by staining for the endothelial marker CD31 (Fig. 1B). Quantitative analysis demonstrated that neovascularization of the discs in cGKI−/− mice was strongly reduced compared with their WT littermates (Fig. 1C).

Disc neovascularization depends on both angiogenesis and vasculogenesis. Therefore, sprouting of pre-existing endothelial cells, which have been reported to express cGKI [20], is likely to be involved in disc neovascularization. To evaluate the role of vasculogenesis, i.e. the involvement of bone marrow-derived progenitor cells, in the impaired neovascularization of sponges implanted into cGKI−/− mice, we examined the capacity of bone marrow-derived progenitors to restore neovascularization in the disc model after their systemic infusion. We injected 10⁶ donor cGKI−/− or WT bone marrow mononuclear cells (BMC) into cGKI−/− recipient mice (Fig. 2A). Intravenous cell therapy with WT but not cGKI-deficient donor BMC clearly rescued the impaired neovascularization of cGKI−/− recipient mice (p<0.01; Fig. 2A). Consistently, neovascularization in WT recipient mice could be strongly enhanced by injection of WT BMC, whereas injection of cGKI−/− BMC had only a weak effect (Fig. 2B). These data imply that cGKI in bone marrow progenitor cells plays an important role to restore postnatal neovascularization in an inflammation-induced neovascularization model in cGKI−/− mice.

To provide further insights into the regulation of vasculogenesis through cGMP-dependent pathways, we examined the role of cGKI on the functional capacity of bone marrow-derived progenitor cells. First, we demonstrated that cGKI is expressed in freshly isolated CD45⁺ hematopoietic bone marrow cells, freshly isolated total bone marrow, as well as cultured bone marrow stromal cells (Fig. 3A+). The most prominent expression of cGKI was found in cultured bone marrow stromal cells, most likely due to the relative enrichment of endothelial cells and fibroblasts in cultured bone marrow stromal cells. To assess the functional capacity of bone marrow-derived progenitor cells, we measured proliferation and apoptosis rates in Lin⁻ sca-1⁺ bone marrow progenitor cells (Fig. 4A−C). BrdU incorporation as a marker of cell proliferation was assessed by flow cytometry and demonstrated a strong reduction in Lin⁻ sca-1⁺ bone marrow progenitor cells from cGKI−/− mice (Fig. 4A+B). Simultaneously, the number of apoptotic Lin⁻ sca-1⁺ bone marrow progenitor cells was increased in cGKI−/− mice as assessed by annexin V binding (Fig. 4C). These results suggest that cGKI promotes proliferation and survival of bone marrow-derived progenitor cells, which contributes to neovascularization.

The cGKI−/− mice used for the above experiments show multiple phenotypes and a reduced life expectancy, which complicates long-term experiments with adult mice and excludes assessment of neovascularization in ischemia models [18,19]. To validate the results obtained in juvenile cGKI−/− mice in an adult model of cGKI deficiency, we also examined the neovascularization capacity of so-called LZM mice [21]. LZM mice carry a mutation in the NH2-terminal protein interaction domain of cGKI that results in disruption of cGKI interactions with key downstream signaling molecules like myosin phosphatase and Rho kinase, but does not reduce the life span of the mutant mice. In line with the results from juvenile cGKI−/− mice, we observed in LZM mice a reduced neovascularization capacity, measured as relative Laser Doppler-derived blood flow, in a model of hindlimb ischemia (Fig. 5A). In addition, the vessel density assessed as number of CD31⁺ capillaries was lower in LZM mice (Fig. 5B). Consistently, the number of spleen-derived vasculogenic progen...
itor cells and vasculogenic colonies was also decreased in LZM mice (Fig. 6A +B). The reduced number and colony formation of vasculogenic progenitors might be involved in the impaired neovascularization of LZM mice. These results suggest that cGKIz in vasculogenic progenitors is also involved in the neovascularization response following ischemia.

Discussion

The major finding of our investigation is a novel role for cGKI in the functionality of bone marrow-derived progenitors. Signaling through cGKI significantly contributed to postnatal neovascularization via stimulation of vasculogenic processes both in the setting of inflammation and following tissue ischemia. Our data implicate that the cGMP-cGKI pathway plays a pivotal stimulatory role for neovascularization, which is at least in part mediated through bone marrow progenitors. cGKII/2 mice exhibit a markedly reduced life span with defects in the relaxation of vascular and visceral smooth muscle cells, disturbed platelets and red blood cells, which limits the availability of adult mice [22–25]. Therefore, we further validated our findings using mice with a mutation in the NH2-terminal protein interaction domain of cGKIa, the so-called leucine zipper mutant (LZM) mice. This mutation selectively inhibits downstream signaling of the cGKIa isoform while leaving the enzyme intact. LZM mice exhibit a vascular phenotype with increased blood pressure, but reach adulthood without limitations in their life span [21]. Consistently, LZM mice exhibited reduced numbers of vasculogenic progenitors and impaired neovascularization following hindlimb ischemia compared to WT mice.

Several previous studies have analyzed the importance of cGMP signaling for neovascularization, particularly for angiogenesis, i.e. the generation of new vessels through local expansion of mature endothelial cells. For instance, systemic cGMP enhancement augmented angiogenesis in ischemic rat brains [26]. Recently, sildenafil, a phosphodiesterase-5 inhibitor, which inhibits cGMP degradation, has been reported to enhance angiogenesis [27]. Moreover, in a mouse model of hindlimb ischemia, sildenafil promoted recovery of vascular perfusion [28]. Based on the use of pharmacological tools it appeared that neovessel growth in this experimental set up was stimulated by a cGMP-cGK pathway that
was independent of nitric oxide production. In line with these previous and our present experiments, a study by Yamahara et al. demonstrated the significance of the natriuretic peptide-cGMP-cGKI pathway for angiogenesis [29]. However, the involvement of cGMP-cGKI signaling in vasculogenesis, i.e. the contribution of bone marrow-derived progenitor cells to postnatal neovascularization, had not been investigated to date. Our results provide evidence that the reduced neovascularization in cGKI−/− mice inferred.

**Figure 4. Functional capacity of BMC from cGKI−/− and WT mice.** (A) Representative FACS analysis of Lin− BMC after pulsing with BrdU for 1 h and staining with BrdU-FITC and sca-1-PE. (B) Proliferation (BrdU+) of sca-1−Lin− bone marrow progenitor cells from cGKI−/− and WT mice (gated on lymphocyte-monocyte fraction; n = 4). (C) Apoptosis (annexinV+) of sca-1−Lin− bone marrow progenitor cells from cGKI−/− and WT mice (gated on lymphocyte-monocyte fraction; n = 3).

doi:10.1371/journal.pone.0004879.g004

**Figure 5. Neovascularization capacity in an unilateral hindlimb ischemia model using LZM and WT mice.** (A) Perfusion is measured as relative Laser Doppler-derived blood flow (n≥5). (B) Number of CD31+ capillaries / mm² in ischemic hindlimbs of LZM versus WT littermates mice (n = 12–18 sections from 4–6 mice / group).

doi:10.1371/journal.pone.0004879.g005
mice is at least in part related to an impaired functional activity of bone marrow-derived progenitors as evidenced by their diminished proliferation and survival, translating into reduced disc neovascularization in vivo. The first description that cGMP stimulation could trigger proliferation of hematopoietic stem cells was provided by Oshita et al. back in 1977 [30]. It is now becoming apparent that the cGMP-cGKI signaling pathway has anti-apoptotic/pro-survival effects in diverse cell types [25,31–34].

About 50% of the cGKI knockout (cGKI−/−) mice die before the age of 5 to 6 weeks [18] representing an important drawback of this model. Therefore, we further corroborated our experimental findings derived from cGKI−/− mice using LZM mice. The apparent spontaneous phenotype of LZM mice is hypertension and vascular contractile dysfunction in both large and resistance arteries, but otherwise these mice appear to develop and age normally. More than ten downstream target substrates for cGKI have been found to date [19]. Currently, however, we have not yet identified the downstream target molecules, which might be affected by the disturbed leucine zipper interactions in bone marrow-derived progenitors.

In vascular smooth muscle cells, cGKI binds to myosin light chain phosphatase (MLCP), which mediates relaxation through a leucine zipper domain-mediated interaction [35]. LZM knockin mice harbor a mutation that disrupts the leucine zipper domain required for cGKIα-mediated regulation of MLCP-induced relaxation [21]. Of note, the level of the mutant cGKIα protein in the vascular wall is comparable to the cGKIα protein level found in WT mice, and mutant cGKIα protein remains responsive to cGMP. Thus, key feature of the LZM mouse model is disruption of interactions between cGKIα and its targets, despite preserved kinase activity.

Collectively, our data highlight the in vivo importance of the cGMP-cGKI pathway for postnatal neovascularization and particularly emphasize the role of the cGKIα isoform in vasculogenesis. Interestingly, a very recent study demonstrated the potential of the cGMP-elevating drug sildenafil to increase the number of circulating vasculogenic progenitor cells in patients with pulmonary arterial hypertension [36]. Further studies using pharmacological cGMP elevation for the pre-treatment of bone marrow-derived progenitors will give more insights into the therapeutic use of modulating the cGMP-cGKI pathway for cardiovascular cell therapy approaches.

Materials and Methods

Animals

The generation of a cGKI null allele (also termed L- allele) by Cre-mediated excision of the loxP-flanked exon 10 of the cGKI gene in germ cells has been described previously [37]. Juvenile (3–5 weeks old) male and female cGKI−/− mice on a 129/Sv genetic background and their wild-type (WT) littermates were used for experiments. Mice with a selective mutation in the NH2-terminal protein interaction domain of cGKIα (LZM mice) have been used at adult age (males, C57BL/6 genetic background, crossed 10 generations, 8–10 weeks old) [21]. LZM mice harbor a discrete mutation in cGKIα that disrupts the leucine zipper (LZ) domain that mediates the interaction of cGKIα with downstream target proteins. In LZM mice the initial four leucine/isoleucine codons in exon1α of the endogenous cGKIα gene were replaced by alanines.

For all invasive procedures, mice were anesthetized with ketamine (100 mg/kg). For induction of hindlimb ischemia, anesthesia was performed using medetomidine (DomitorTM; Pfizer, Karlsruhe, Germany; 0.1 mg/kg). For post-operative analgesia carprofen (RimadylTM; Pfizer; 5 mg/kg) was administered. All animal protocols were approved by the Institutional Animal Care and Use Committee (Regierungspra¨sidium Darmstadt, Germany).

BrdU proliferation assay

Total bone marrow cells were obtained by flushing femur and tibia bones with PBS using 27-gauge needles. Then, cells (10⁶ / ml) were resuspended in RPMI 1640 medium+10% fetal calf serum (both from Invitrogen, Karlsruhe, Germany), and pulsed with 10 μM BrdU (BrdU flow kit, BD biosciences (BD), Heidelberg, Germany) for one hour. Staining of surface antigens with a cocktail of biotinylated antibodies against lineage markers (lineage marker panel: anti-CD3, anti-B220, anti-CD11b, anti-Gr, anti-TER119) was performed for 20 min on ice. This step was followed
by streptavidin-APC (BD) together with sca-1-PE (BD) staining for another 20 min on ice. Cells were fixed and permeabilized with Cytotox / Cytoperm buffer according to the manufacturer’s instructions (BD LSR kit) and treated with DNase prior to intracellular staining with FITC-labeled BrdU for 20 min at room temperature. Stained cells were then analyzed by flow cytometry using a FACS Calibur (BD) using CellQuest software. Specific cell fluorescence intensity was calculated by subtracting the signal obtained with isotype-matched control antibodies (BD).

**Apoptosis assay**

Total bone marrow cells were cultured for 24 h in ex-vivo 10 medium + 100 ng/ml murine SCF (Peprotech, Rocky Hill, NJ). Then, bone marrow cells were stained with the biotinylated lineage marker panel (BD) for 20 min on ice, followed by streptavidin-PE (BD) together with sca-1-FITC and annexinV-APC (both BD) for another 20 min at room temperature using annexin binding buffer (BD). Cells were then immediately analyzed by flow cytometry using a FACS Calibur.

**Vasculogenic progenitor assay**

Spleens were aseptically removed, homogenized, and laid over Ficoll solution (Boehringer, Mannheim, Germany). Mononuclear cells were obtained from the Ficoll’s interphases and washed with PBS. Then, 4 x 10⁶ cells per well were seeded on fibronectin-coated 24-well plates (10 µg/ml fibronectin in PBS for 1 h at room temperature; Sigma-Aldrich, Tautkirchen, Germany) and cultured in 500 µl EBM medium + 20% FCS + supplements (Cambrex Bio Science, Verviers, Belgium) at 37°C. After 4 days of culture, vasculogenic progenitors were assayed by co-staining with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (DiLDL; CellSystems, St. Katharinen, Germany) and FITC-conjugated lectin (Sigma-Aldrich) [38].

To obtain colonies with vasculogenic activity, we used a modified version of the protocol of Ingram et al. [39] using fibronectin and supplemented EBM medium scoring clusters of cells after 7 days.

**Western blot analysis**

Total bone marrow cells, CD45⁺ bone marrow leukocytes, and cultured bone marrow stromal cells were used for Western blot analysis. CD45⁺ cells were isolated by immunomagnetic selection using magnetic lineage marker panel (BD) for 20 min on ice, followed by streptavidin-PE (BD) together with sca-1-FTTC and annexinV-APC (both BD) for another 20 min at room temperature using annexin binding buffer (BD). Cells were then immediately analyzed by flow cytometry using a FACS Calibur.

**Hind limb ischemia model**

To induce unilateral hind limb ischemia, the proximal portion of the right femoral artery including the superficial and the deep branch were occluded using an electrical coagulator. The overlying skin was closed using surgical staples. Limb perfusion was assessed with a laser Doppler blood flow imager (Laser Doppler Perfusion Imager System, moorLDI™-Mark 2, Moor Instruments, Wilmington, Delaware) after one week. Before initiating scanning, animals were placed on a heating pad at 37°C to minimize variations in temperature. Calculated perfusion is expressed as the ratio of ischemic to non-ischemic hind limb perfusion.

**Histology**

Capillaries were scored in 8 µm frozen sections of the adductor muscles by staining for CD31 (PE-labeled; BD Biosciences). Images were obtained by confocal microscopy (LSM 510 Meta, Zeiss, Germany).

**Statistical analysis**

Results are expressed as mean ± SEM. Overall comparison of the treatment groups was performed with the Kruskal-Wallis test followed by post-hoc pairwise comparison using the Mann-Whitney test. P values < 0.05 were considered statistically significant. Analyses were performed with SPSS 15.0 (SPSS Inc.).

**Acknowledgments**

We are indebted to Christiane Mildner-Rühl, Tino Roese, Ariane Fischer, Marion Mahly-Reinholz, Barbara Birk, and Jaimy Saif for their excellent assistance.

**Author Contributions**

Conceived and designed the experiments: AA CH SF MEM RF SD. Performed the experiments: AA CH SF RF. Analyzed the data: AA CH RF SD. Contributed reagents/materials/analysis tools: SF FH MEM RF. wrote the paper: AA CH RF SD. Made critical revision of the drafted manuscript for important intellectual content: FH MEM.

**References**

1. Murakawa T, Asahara T, Silver M, Bauters C, Masuda H, et al. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567–2578.

2. Aicher A, Hoesschen C, Mildner-Rühl C, Urbich C, Biling C, et al. (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370–1376.
3. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31.

4. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674.

5. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, et al. (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434–438.

6. Shi Q, Raffi S, Wu MH, Wijelath ES, Yu C, et al. (1998) Evidence for circulating bone marrow-derived endothelial cells. Blood 92: 362–367.

7. Hokura A, Luedemann G, Shastry S, Hanley A, Kearney M, et al. (2003) Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108: 3115–3121.

8. Landi U, Werner N, Link A, Endres M, Wustmann S, et al. (2004) Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109: 220–226.

9. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1935–1939.

10. Suntanham AV, d’Uschio LV, Peterson TE, Katusic ZS (2008) Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 29: 1451–1455.

11. Homig B, Arakawa N, Kohler C, Drexler H (1998) Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97: 363–368.

12. Thun T, Fracarollo D, Schultheiss H, Froese S, Galuppo P, et al. (2007) Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56: 660–674.

13. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, et al. (2007) Diabetic control, not diabetes itself, is responsible for profound reduction in neovascularization and function in diabetes. Proc Natl Acad Sci U S A 104: 1615–1622.

14. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, et al. (2006) Ex vivo expansion of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615–1622.

15. Senthilkumar A, Smith RD, Khitha J, Arora N, Veerareddy S, et al. (2007) Sildenafil promotes angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211: 197–204.

16. Senhilikumar A, Smith RD, Khatia J, Azora N, Veerareddy S, et al. (2007) Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol 27: 1947–1954.

17. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, et al. (2003) Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A 100: 3400–3409.

18. Oshita AK, Rothstein G, Lonngi G (1997) cGMP stimulation of stem cell proliferation. Blood 99: 585–591.

19. Chan NL, Fiscus RR (2003) Guanylyl cyclase inhibitors NS8028 and ODQ and protein kinase G (PKG) inhibitor KT58832 trigger apoptotic DNA-fragmentation in immortalized urethral epithelial cells: anti-apoptotic effects of basal cGMP/PKG. Mol Hum Reprod 9: 757–783.

20. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, et al. (2006) cGMP-dependent protein kinase type I inhibits TAB1/p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 281: 73281–73287.

21. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, et al. (2001) Nicotine stimulates angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and cGMP After Stroke in the Rat. Circ Res 89: 308–313.

22. Pyrochou A, Zhou Z, Koika V, Petrour C, Coordopatis P, et al. (2007) The phosphodiesterase 3 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211: 197–204.

23. Milkereit B, Krall P, Sausber M, Klaar P, Bauer M, Pfeifer A, et al. (1999) Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 189: 1253–1264.

24. Li Z, Xi X, Gu M, Feil R, Ye RD, et al. (2003) A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation. Cell 112: 77–86.

25. Foller M, Feil S, Ghersich K, Soka S, Gerling A, et al. (2008) Anemia and sphenomegaly in cGKI-deficient mice. Proc Natl Acad Sci U S A 105: 6761–6766.

26. Zhang R, Wang L, Zhang J, Chen J, Zhi Z, et al. (2003) Nitric Oxide Enhances Angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and cGMP After Stroke in the Rat. Circ Res 92: 308–313.

27. Sajjan AP, Fiscus RR (2003) 5-Azacytidine inhibits proliferation of bone marrow-derived endothelial progenitor cells. Blood 102: 2752–2760.

28. Pyrochou A, Zhou Z, Koika V, Petrour C, Coordopatis P, et al. (2007) The phosphodiesterase 3 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211: 197–204.

29. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, et al. (2001) Nicotine stimulates angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and cGMP After Stroke in the Rat. Circ Res 89: 308–313.

30. Miltenyi B, Bouma BN (2002) Angiogenesis monitored by perfusion with a space-filling microbead suspension. Mol Ther 1: 82–87.